Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Terminated
Recruitment failure
Other terminated trials from GERCOR - Multidisciplinary Oncology Cooperative Group
- Digestive Neuroendocrine Tumors · Phase PHASE3 · Oct 2018
- Colorectal Cancer Metastatic · Phase PHASE2 · Jan 2017
- Colorectal Cancer · Phase PHASE2 · Dec 2014
- Chemotherapeutic Agent Toxicity · Phase PHASE3 · Dec 2012
More terminations from GERCOR - Multidisciplinary Oncology Cooperative Group
Other Colorectal Adenocarcinoma trials with similar outcome
A PHASE2 clinical study on Colorectal Adenocarcinoma and Oesogastric, this trial is terminated or withdrawn. The trial is conducted by GERCOR - Multidisciplinary Oncology Cooperative Group and has accumulated 7 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Mar 2022 — Oct 2023 [monthly]
Recruiting PHASE2
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Servier
For direct contact, visit the study record on ClinicalTrials.gov .